



The Role of Immunity in the Tumor Microenvironment

Guest Editor:

Dr. Nand K Roy

La Jolla Institute for
Immunology, California, CA, USA

Deadline for manuscript
submissions:

closed (15 July 2024)

Message from the Guest Editor

It is now well established that the tumor microenvironment plays a tremendous role in cancer progression and regulating therapeutic response. Of all the therapeutic modalities affected by the TME, immunotherapies are also influenced by the participation of different regulatory molecules from immune cells and components of the TME. The latest developments in the field of immunology have significantly improved the efficacy of diverse immunotherapies, such as monoclonal antibody (MAB) therapy, immune checkpoint blockade (ICB) therapy, vaccines, CAR-T therapy, etc., against cancer cells. However, the understanding of the immune system in the TME still requires an in-depth understanding as it is now well recognized that the presence of different innate and adaptive immune cells in the TME can provide both pro- and anti-tumorigenic immunity against cancer cells. Thus, this Special Issue invites manuscripts in the form of original research articles, reviews, etc., related to the role of immunity in the TME to ultimately broaden the understanding of how to target cancer cells efficiently.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)